AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

2(Previously Presented). The method according to claim 4, wherein said compound of formula I and said selective estrogen receptor modulator are delivered in a single composition.

3(Previously Presented). The method according to claim 4, wherein said compound of formula I and said selective estrogen receptor modulator are delivered separately.

4(Currently Amended). A method of inducing contraception comprising delivering to a female of child-bearing age a composition comprising a compound of formula I in a regimen which involves delivering a pharmaceutically effective amount of one or more selective estrogen receptor modulator selected from the group consisting of EM-800, EM-652, raloxifene hydrochloride, arzoxifene, lasofoxifene, droloxifene, tamoxifen citrate, 4-hydroxytamoxifen citrate, clomiphene citrate, toremifene citrate, pipendoxifene, idoxifene, levormeloxifene, centchroman, nafoxidene, and bazedoxifene to said female, wherein formula I is:



I

wherein:

R^1 and R^2 are joined to form ~~a ring selected from the group consisting of~~

~~$-CH_2(CH_2)_nCH_2-$, $-CH_2CH_2C(CH_3)_2CH_2CH_2-$, $-O(CH_2)_mCH_2-$, $-O(CH_2)_pO-$, $-CH_2CH_2OCH_2CH_2-$, $-CH_2CH_2N(H)CH_2CH_2-$, and $-CH_2CH_2N(alkyl)CH_2CH_2-$;~~

~~m is an integer from 1 to 4;~~

n is ~~an integer from 1~~ 4 or ~~to~~ 5;

~~p is an integer from 1 to 4;~~

~~or R^1 and R^2 form a double bond to $C(CH_3)_2$, C(cycloalkyl), O, or C(cycloether);~~

R^3 is ~~selected from the group consisting of H, OH, NH_2, C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, C_2 to C_6 alkenyl, substituted C_2 to C_6 alkenyl, alkynyl, substituted alkynyl, and COR^A~~;

~~R^A is selected from the group consisting of H, C_1 to C_3 alkyl, substituted C_1 to C_3 alkyl, C_1 to C_3 alkoxy, substituted C_1 to C_3 alkoxy, C_1 to C_3 aminoalkyl, and substituted C_1 to C_3 aminoalkyl;~~

R^4 is ~~selected from the group consisting of H, halogen, CN, NH_2, C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, C_1 to C_6 alkoxy, substituted C_1 to C_6 alkoxy, C_1 to C_6 aminoalkyl, and substituted C_1 to C_6 aminoalkyl;~~

R^5 is a five membered heterocyclic ring having ~~1, 2, or 3~~ heteroatoms selected from the group consisting of O, S, SO, ~~SO_2~~ and NR^6 and having one or two independent substituents from the group consisting of H, halogen, CN, ~~NO_2,~~ C_1 to C_3 ~~C_4~~ alkyl, ~~substituted C_1 to C_4 alkyl, C_1 to C_3 alkoxy, substituted C_1 to C_3 alkoxy, C_1 to C_3 aminoalkyl, substituted C_1 to C_3 aminoalkyl, COR^D,~~ and CSR^D, ~~and NR^ECOR^D~~;

R^D is ~~H, NH_2, C_1 to C_3 alkyl, substituted C_1 to C_3 alkyl, aryl, substituted aryl, C_1 to C_3 alkoxy, substituted C_1 to C_3 alkoxy, C_1 to C_3 aminoalkyl, or substituted C_1 to C_3 aminoalkyl~~;

~~R^E is H, C_1 to C_3 alkyl, or substituted C_1 to C_3 alkyl;~~

R^6 is H, or C_1 to C_3 alkyl~~, substituted C_1 to C_3 alkyl, or C_1 to C_4CO_2alkyl~~;

Q^1 is S;

or a pharmaceutically acceptable salt, tautomer, metabolite, or prodrug thereof.

5(Previously Presented). The method according to claim 4, wherein said compound is delivered at a daily dosage of about 0.1 to about 50 mg.

6(Previously Presented). The method according to claim 4, wherein said regimen comprises delivering said composition daily for 1 to about 21 days, wherein said regimen is a cycle which is repeated monthly.

7(Previously Presented). The method according to claim 4, wherein said selective estrogen receptor modulator is delivered at a daily dosage of about 0.2 to about 100 mg.

8(Canceled).

9(Previously Presented). The method according to Claim 4, wherein ~~R^3 and R^3 are joined to form the $-CH_2(CH_2)_nCH_2-$ ring; n is 3; R^3 and R^4 are H;~~ R^5 is the five membered ring having the structure:

U is O, S, or NR^6;

X' is selected from the group consisting of halogen, CN, ~~NO_2, $CONH_2$,~~ and $CSNH_2$, ~~COR^B, CSR^B,~~ ~~C_1 to C_3 alkyl, and C_1 to C_3 alkoxy;~~

~~R^B is C_1 to C_3 aminoalkyl or substituted C_1 to C_3 aminoalkyl, wherein said aminoalkyl is NH(alkyl) or N(alkyl)$_2$;~~

Y' is ~~selected from the group consisting of H, halogen, and C_1 to C_4 alkyl, wherein said halogen is F~~.

10-11(Canceled).

12-13(Canceled).

14(Currently Amended). The method according to claim 4, wherein said compound is selected from the group consisting of 4-(1',2'-Dihydro-2'-thioxospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)-2-thiophenecarbonitrile, 4-Methyl-5-(1,2-dihydro-2-thioxospiro[cyclohexane-1,3-[3H]-indol]-5-yl)-2-thiophenethioamide, 5-(1,2-Dihydro-2-thioxospiro[cyclopentane-1,3-[3H]indol]-5'-yl)-1H-pyrrole-2-carbonitrile, ~~5-(1,2-Dihydro-2-thioxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-1-(tert-butoxycarbonyl)-pyrrole-2-carbonitrile,~~ 5-(1,2-Dihydro-2-thioxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-1-H-pyrrole-2-carbonitrile, 5-(2'-thioxospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)-1-methyl-pyrrole-2-carbonitrile, 5-(1,2-Dihydro-2-thioxospiro[cyclopentane-1,3-[3H]indol]-5-yl)-3-thiophenecarbonitrile, 5-(1,2-Dihydro-thioxospiro[cyclopentane-1,3-[3H]indol]-5-yl)-2-thiophenecarbonitrile, ~~4-(3,3-dimethyl-2-thioxo-2,3-dihydro-1H-indol-5-yl)-2-furonitrile,~~ 5-(5-Chloro-2-thienyl)spiro[cyclohexane-1,3-[3H]indol]-2(1H)-thione, 5-(1,2-Dihydro-2-thioxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-3-furancarbonitrile, 5-(1,2-Dihydro-2-thioxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-4-propyl-2-thiophenecarbonitrile, 4-(1,2-Dihydro-2-thioxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-2-furancarbonitrile, 5-(1",2"-Dihydro-2"-thioxospiro[cyclohexane-1,3"-[3H]indol]-5"-yl)-4-methyl-2-thiophenecarbonitrile, 5-(1",2"-Dihydro-2"-thioxospiro[cyclohexane-1,3"-[3H]indol]-5"-yl)-2-thiophenecarbonitrile, ~~5-(1,2-Dihydro-2-thioxospiro[cyclohexane-1,3-[3H]indol]-5-yl)-4-n-butyl-2-thiophenecarbonitrile,~~ and a pharmaceutically acceptable salt, tautomer, metabolite, or prodrug thereof.

15-43(Canceled).